Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069021 | 0.76 | NISCH (0.39) | CA2HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL2071541 | 0.76 | NISCH (0.39) | CA2HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL6069296 | 0.76 | NISCH (0.39) | CA2HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL18365857 | 0.75 | CA2 (0.47) | CYP19A1CA2HTR1ASLC6A2HTR2C | |
| SCHEMBL3356952 | 0.73 | MAPT (0.39) | CYP19A1CA2HTR1ASLC6A2HTR2C | |
| SCHEMBL3329915 | 0.70 | CTNNB1 (0.47) | MAPTALDH1A1GAAHSD17B10EPHX2 | |
| Hydrochloric Acid SCHEMBL21810836 | 0.70 | HTR7 (0.40) | CYP19A1CA2 | |
| Hydrochloric Acid SCHEMBL21810835 | 0.70 | HTR7 (0.40) | CYP19A1CA2 | |
| SCHEMBL6068844 | 0.68 | MAP3K14 (0.35) | SLC6A2 | |
| SCHEMBL6068846 | 0.68 | MAP3K14 (0.35) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109234-B2 | Benzoxathiepine derivatives and their use as medicines | PIERRE FABRE MEDICAMENT (FR) | 2006-09-19 | — | — | US | disclosed |
| CN-1264836-C | Benzoxathiepine derivatives and their use in the preparation of medicaments | PF MEDICAMENT (FR) | 2006-07-19 | — | — | CN | disclosed |
| EP-1370547-B1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PF MEDICAMENT (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20040127552-A1 | Benzoaxathiepin derivatives and their use as medicines | PIERRE FABRE MEDICAMENT (FR) | 2004-07-01 | — | — | US | disclosed |
| CN-1505623-A | Benzoxathiepine derivatives and their use as pharmaceuticals | Ƥ����������ҽҩ��˾ | 2004-06-16 | — | — | CN | disclosed |
| EP-1370547-A1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002081464-A1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127552-A1 | Benzoaxathiepin derivatives and their use as medicines | CYP4A11, CYP3A4, CYP4F11 | CYP19A1 31/4885CA2 1927/4885HTR1A 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.